UA118658C2 - СПОСІБ ДІАГНОСТИКИ ПРОГНОЗУ ВІДПОВІДІ НА ІНГІБІТОР TNFα - Google Patents

СПОСІБ ДІАГНОСТИКИ ПРОГНОЗУ ВІДПОВІДІ НА ІНГІБІТОР TNFα

Info

Publication number
UA118658C2
UA118658C2 UAA201504849A UAA201504849A UA118658C2 UA 118658 C2 UA118658 C2 UA 118658C2 UA A201504849 A UAA201504849 A UA A201504849A UA A201504849 A UAA201504849 A UA A201504849A UA 118658 C2 UA118658 C2 UA 118658C2
Authority
UA
Ukraine
Prior art keywords
tnf
inhibitor
diagnostic method
predicting response
treatment
Prior art date
Application number
UAA201504849A
Other languages
English (en)
Inventor
Ласло НАДЬ
Берталан Мєшко
Ласло Штєінер
Габор Захуцкі
Жолт Холло
Original Assignee
Егіш Дьодьсзердьяр Зрт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Егіш Дьодьсзердьяр Зрт. filed Critical Егіш Дьодьсзердьяр Зрт.
Publication of UA118658C2 publication Critical patent/UA118658C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Винахід стосується способу in vitro прогнозування того, чи відповідатиме пацієнт, який має ревматоїдний артрит, на лікування інгібітором TNF(, при цьому спосіб включає визначення рівня експресії генів CNTNAP3, CYP4F3, GZMB, ММЕ, МХ1, RAVER2, SERPINB10 та TNFAIP6 або рівня експресії генів CNTNAP3, CYP4F3, EPSTІ1, ММЕ, RGS1, SERP1NB10 та TNFAIP6, або рівня експресії генів FCGR3A, GPAM, GZMB, IFI35, ММЕ, PTGS2, RAVER2, RFC1 та RSAD2, в зразку крові згаданого пацієнта.
UAA201504849A 2012-10-19 2013-10-18 СПОСІБ ДІАГНОСТИКИ ПРОГНОЗУ ВІДПОВІДІ НА ІНГІБІТОР TNFα UA118658C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1200607A HU230680B1 (hu) 2012-10-19 2012-10-19 Diagnosztikai eljárás
PCT/HU2013/000101 WO2014060785A2 (en) 2012-10-19 2013-10-18 DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFα INHIBITOR

Publications (1)

Publication Number Publication Date
UA118658C2 true UA118658C2 (uk) 2019-02-25

Family

ID=89990915

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201504849A UA118658C2 (uk) 2012-10-19 2013-10-18 СПОСІБ ДІАГНОСТИКИ ПРОГНОЗУ ВІДПОВІДІ НА ІНГІБІТОР TNFα

Country Status (12)

Country Link
US (1) US20160194709A1 (uk)
EP (1) EP2909340B1 (uk)
JP (1) JP2016502400A (uk)
CA (1) CA2889087C (uk)
DK (1) DK2909340T3 (uk)
EA (1) EA037105B1 (uk)
ES (1) ES2645972T3 (uk)
HU (1) HU230680B1 (uk)
NO (1) NO2909340T3 (uk)
PL (1) PL2909340T3 (uk)
UA (1) UA118658C2 (uk)
WO (1) WO2014060785A2 (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179469A1 (en) * 2015-05-07 2016-11-10 Abbvie Inc. Methods and compositions for diagnosing and treating inflammatory bowel disease
JP2018527895A (ja) 2015-06-29 2018-09-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法
GB2547406A (en) * 2015-11-20 2017-08-23 Folkersen Lasse Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
EP3433271A4 (en) * 2016-03-23 2019-11-27 Regents of the University of Minnesota PROCEDURE FOR DETECTING APOBEC3 EXPRESSION AND PREDICTING CLINICAL RESULTS
US20200399698A1 (en) * 2018-02-19 2020-12-24 Genefron Ltd. Methods of determining response to tnf alpha blockers
EP3765634A4 (en) 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES
WO2020111887A1 (ko) * 2018-11-30 2020-06-04 차의과학대학교 산학협력단 뇌 유래 소포체 특이적 마커 및 이를 이용한 뇌 질병 진단 방법
US20220073988A1 (en) * 2018-12-07 2022-03-10 Dna Chip Research Inc. Method for predicting efficacy of rheumatoid arthritis therapeutic agent and biomarker used therein
WO2020264426A1 (en) 2019-06-27 2020-12-30 Scipher Medicine Corporation Developing classifiers for stratifying patients
KR102429261B1 (ko) * 2020-08-25 2022-08-03 충북대학교 산학협력단 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058362A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
ES2322267T3 (es) * 2003-04-09 2009-06-18 Genentech, Inc. Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa.
EP1857559A1 (en) * 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
WO2008122007A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
US8092998B2 (en) * 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
CN102171365B (zh) * 2008-08-25 2014-01-29 森托科尔奥索生物科技公司 用于溃疡性结肠炎和相关疾病的抗tnf治疗的生物标记物
JP2011004743A (ja) * 2009-06-26 2011-01-13 Dna Chip Research Inc 関節リウマチ患者におけるインフリキシマブ薬効の有効性を判別する方法
WO2012061620A1 (en) * 2010-11-04 2012-05-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis

Also Published As

Publication number Publication date
WO2014060785A3 (en) 2014-06-12
DK2909340T3 (da) 2017-11-13
CA2889087A1 (en) 2014-04-24
ES2645972T3 (es) 2017-12-11
WO2014060785A2 (en) 2014-04-24
EP2909340B1 (en) 2017-08-02
EA037105B1 (ru) 2021-02-05
EA201590773A1 (ru) 2015-09-30
JP2016502400A (ja) 2016-01-28
US20160194709A1 (en) 2016-07-07
PL2909340T3 (pl) 2018-01-31
CA2889087C (en) 2021-11-16
NO2909340T3 (uk) 2017-12-30
HU230680B1 (hu) 2017-08-28
HUP1200607A2 (en) 2014-04-28
EP2909340A2 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
UA118658C2 (uk) СПОСІБ ДІАГНОСТИКИ ПРОГНОЗУ ВІДПОВІДІ НА ІНГІБІТОР TNFα
IL262648B (en) Gene expression profile algorithm and test based on cellular organization group score and stromal response group score for determining prognosis of prostate cancer
IL236181A0 (en) Methods for detecting diseases or conditions
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
EP2709543A4 (en) INSTRUMENTS AND METHODS FOR EXPANSION
IN2014MN00848A (uk)
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
EP2904115A4 (en) BIOMARKERS AND METHODS FOR PREDICTING RESPONSE TO INHIBITORS AND USES THEREOF
NZ630421A (en) Biomarkers predictive for clinical response for glatiramer acetate
IL236182A0 (en) Methods for detecting diseases or conditions using circulating diseased cells
EP2596117A4 (en) METHOD FOR DETECTING NIERGENICAL DISEASES OR SUFFERING
GB201207722D0 (en) Method
EP2542699A4 (en) METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
EP2622101A4 (en) GENETIC VARIATIONS OF INTERLEUKIN-6 RECEPTOR GENE FOR PREDICTING PATIENT RESPONSE TO TREATMENT BASED ON INHIBITORS OF INTERLEUKIN-6 RECEPTOR
EP2596349A4 (en) PROCEDURE FOR DETECTING CARDIOVASCULAR DISEASES OR SUFFERING
BR112015022977A2 (pt) métodos para predição de risco de metástase em melanoma cutâneo
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX365302B (es) Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno.
SG11201507521UA (en) Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)
IN2014DN09655A (uk)
GB201101400D0 (en) Detection method
MX2015017535A (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.
WO2012016030A3 (en) Inflammation detection
NZ706192A (en) Mir-18b for use as a marker of cancer progression and target for therapies to treat cancer